Palivizumab for the prevention of respiratory syncytial virus (RSV) in premature infants

Trial Profile

Palivizumab for the prevention of respiratory syncytial virus (RSV) in premature infants

Completed
Phase of Trial: Phase III

Latest Information Update: 07 May 2013

At a glance

  • Drugs Palivizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Acronyms IMpact-RSV
  • Most Recent Events

    • 07 May 2013 Results presented at the 2013 Annual Meeting of the Pediatric Academic Societies.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top